These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 28717990)

  • 1. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
    Locatelli F; Del Vecchio L
    J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal phosphate control: still an unmet need in chronic kidney disease patients.
    Locatelli F; Del Vecchio L
    Expert Opin Pharmacother; 2014 Feb; 15(3):307-9. PubMed ID: 24283572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
    St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
    Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
    Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
    Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
    Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
    Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation phosphate binders: focus on iron-based binders.
    Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
    Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron-based Phosphate Binders for ESRD Patients].
    Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current approaches in the treatment of hyperphosphatemia in chronic kidney disease].
    Matuszkiewicz-Rowińska J; Kościelska M
    Wiad Lek; 2017; 70(6 pt 2):1161-1165. PubMed ID: 29533905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
    Pai AB; Jang SM; Wegrzyn N
    Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
    Schmid H; Lederer SR
    Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating hyperphosphatemia - current and advancing drugs.
    Ketteler M; Liangos O; Biggar PH
    Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.